- Q3 Adj. EPS of $3.82 beats $3.74 consensus; Net Revenue of $17.40B beats $17.34B est.
- Key drugs Skyrizi ($5.78B vs $5.74B) and Humira ($683M vs $679.3M) top estimates.
- FY Adj. EPS guidance raised to $13.95-$13.99 from $13.76-$13.96 previously.
?? Positive AI Sentiment (+6.5 / 10)
Observed market reaction after signal
4h +1.24% · 24h +1.41% · Peak +2.73%